2022
DOI: 10.1016/j.ijmedinf.2021.104626
|View full text |Cite
|
Sign up to set email alerts
|

Clinical decision support systems with team-based care on type 2 diabetes improvement for Medicaid patients: A quality improvement project

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
2
1

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(11 citation statements)
references
References 22 publications
0
9
0
Order By: Relevance
“…Glucose Path, an AI-enabled CDSs for diabetes, effectively reduces the glucose level of patients with poorly controlled diabetes in the Medicaid population. These CDSs facilitate team-based care allowing a cost-effective solution to be produced for patients [13]. GlycASSIST, another diabetes CDS, facilitated treatment intensification and was acceptable to patients with diabetes and general practitioners [14].…”
Section: Discussionmentioning
confidence: 99%
“…Glucose Path, an AI-enabled CDSs for diabetes, effectively reduces the glucose level of patients with poorly controlled diabetes in the Medicaid population. These CDSs facilitate team-based care allowing a cost-effective solution to be produced for patients [13]. GlycASSIST, another diabetes CDS, facilitated treatment intensification and was acceptable to patients with diabetes and general practitioners [14].…”
Section: Discussionmentioning
confidence: 99%
“…As healthcare transitions towards a more patient-centric model, CDSS can significantly improve patient engagement by providing them access to easy-to-understand information, allowing them to be active participants in their care journey. 76 …”
Section: Current State Of Cdssmentioning
confidence: 99%
“…After removing duplicated publications, 9607 (83%) studies were available for title and abstract screening. Finally, 237 (2.5%) studies were evaluated based on their full text, and 85 (35.9%) studies [23, (including 13/18, 15%, conference abstracts) were selected for analysis. The PRISMA-ScR flow diagram is shown in Figure 1 and the PRISMA-ScR checklist in Multimedia Appendix 2.…”
Section: Search and Selectionmentioning
confidence: 99%
“…Valid studies (n=75, 88%) c [28,30,32,40,43,48,52,59,63,64,69,71,77,80,83,86,97,99,104,109] 20 (27) <6 months [31, 33, 36-39, 41, 45-47, 49-51, 55-57, 61, 62, 65, 68, 74-76,78, 81, 84, 85, 87, 88, 92, 95, 96, 100-102, 107, 108, 111] 38 (51) 6-11 months [23,29,34,35,42,44,53,79,93,98 Unapplicable studies d a In 3 (4%) studies, the study design was a randomized controlled trial (RCT) cross-over; the follow-up period was defined as the overall study duration including the washout period for cross-over studies. b Number of studies and percentages were presented.…”
Section: References Studies N (%) B Characteristic and Categories For...mentioning
confidence: 99%
See 1 more Smart Citation